If you want more energy, focus on CoQ10 and NMN
A competing pill from Eli Lilly is also expected to receive FDA approval in the coming months, setting the stage for a brand-new era of GLP-1 competition
Participants receiving semaglutide 2.4 mg weekly achieved an average weight loss of 14.9% of body weight over 68 weeks, compared to just 2.4% with placebo (Wilding et al., 2021, PMID: 33567185)
In the current study, the decrease in CAT activity was observed, despite the overall increase in antioxidant markers , which may be attributed to the predominantly intracellular localization of CAT
How GLP-1 Agonist Injections Work GLP-1 Agonist, commonly known under the brand name WegovyTM, is an injectable glucagon-like peptide-1 (GLP-1) receptor agonist